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Abstract
The four glycoforms of the cellular prion protein (PrPC) variably glycosylated at the two N-linked glycosylation sites are
converted into their pathological forms (PrPSc) in most cases of sporadic prion diseases. However, a prominent molecular
characteristic of PrPSc in the recently identified variably protease-sensitive prionopathy (VPSPr) is the absence of a
diglycosylated form, also notable in familial Creutzfeldt-Jakob disease (fCJD), which is linked to mutations in PrP either from
Val to Ile at residue 180 (fCJDV180I) or from Thr to Ala at residue 183 (fCJDT183A). Here we report that fCJDV180I, but not
fCJDT183A, exhibits a proteinase K (PK)-resistant PrP (PrPres) that is markedly similar to that observed in VPSPr, which exhibits
a five-step ladder-like electrophoretic profile, a molecular hallmark of VPSPr. Remarkably, the absence of the diglycosylated
PrPres species in both fCJDV180I and VPSPr is likewise attributable to the absence of PrPres glycosylated at the first N-linked
glycosylation site at residue 181, as in fCJDT183A. In contrast to fCJDT183A, both VPSPr and fCJDV180I exhibit glycosylation at
residue 181 on di- and monoglycosylated (mono181) PrP prior to PK-treatment. Furthermore, PrPV180I with a typical
glycoform profile from cultured cells generates detectable PrPres that also contains the diglycosylated PrP in addition to
mono- and unglycosylated forms upon PK-treatment. Taken together, our current in vivo and in vitro studies indicate that
sporadic VPSPr and familial CJDV180I share a unique glycoform-selective prion formation pathway in which the conversion of
diglycosylated and mono181 PrPC to PrPSc is inhibited, probably by a dominant-negative effect, or by other co-factors.
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Introduction
Prion diseases are a group of fatal transmissible spongiform
encephalopathies affecting both animals and humans. Human
prion diseases are highly heterogeneous: They can be inherited,
sporadic, or acquired, and include various forms of Creutzfeldt-
Jakob disease (CJD), Gerstmann-Stra¨ussler-Scheinker (GSS) dis-
ease, fatal insomnia, and kuru. Moreover, regardless of differences
in phenotypes, they are all caused by infectious pathologic prions
(PrPSc) that are derived from the cellular prion protein (PrPC)
through a conformational transition [1]. The partially proteinase
K (PK)-resistant PrP27–30 (PrPres) is the molecular hallmark of all
human prion diseases. On Western blots three major PrP bands
are typically observed but composed of a di-, two mono-, and an
unglycosylated PrP glycoforms because the two individually
monoglycosylated PrP at asparagine residues N181 and N197
partially overlap. There are a few exceptions [2–5]. Of them, all
but one are associated generally with PrP mutations showing
different PrP banding patterns, as in GSS and familial CJD. GSS
is characterized by the presence of additional small PK-resistant
PrP fragments, whereas fCJD linked to either PrPT183A or PrPV180I
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mutations exhibits a PrPres that lacks the diglycosylated PrP species
[2–4].
The abnormal PrP associated with the recently identified prion
disease termed variably protease-sensitive prionopathy (VPSPr)
has highly distinctive features [6,7], including a one that was
initially reported as an atypical sCJD by Giaccone et al [8].
Although there is no PrP mutation in the open reading frame of
the PrP gene, VPSPr is associated with a PrPres that bears three of
the characteristics of inherited rather than sporadic prion diseases.
First, the diglycosylated PrPSc in VPSPr is virtually undetectable,
as it is also with PrPres in fCJDV180I and fCJDT183A [3,4,7].
Second, VPSPr is characterized by the presence in the brain of
more than three PrPres fragments including a ,7 kDa fragment, a
characteristic of GSS [2,7]. However, in marked contrast to PrPres
in GSS, PrPres in VPSPr is preferentially detected with the 1E4
antibody instead of the widely used 3F4 antibody, forming a
pathognomonic five-step ladder-like PrP electrophoretic profile
[7]. Finally, in some VPSPr cases, a positive family history of
cognitive impairment was observed [6,7]. Clearly, the PrPSc
associated with VPSPr is distinct from the prion strains associated
with other sporadic prion diseases. The molecular mechanism
underlying the formation of the peculiar prion in VPSPr has yet to
be determined.
Compared to PrP in the most common sporadic CJD (sCJD), a
significant decrease in the ratio of diglycosylated PrP to
monoglycosylated PrP treated with or without PK was reported
in fCJDT183A previously [3]. This is because the T183A PrP
mutation completely abolishes the first N-linked glycosylation site
at residue 181 (N181) [9–11] and the detected diglycosylated PrP
is derived only from wild-type PrP (3, the current study). In
contrast, the PrP glycoforms in VPSPr appear typical prior to PK-
treatment; however, there is no detectable diglycosylated PrPSc
after PK-treatment. As with VPSPr, the molecular mechanism
underlying the absence of the diglycosylated PrP in fCJDV180I is
unclear [4]. Using a combination of in vivo and in vitro assays, our
current study indicates that the absence of the diglycosylated PrPSc
in both VPSPr and fCJDV180I results from a glycoform-selective
prion formation pathway associated with the inability of the di-
and mono-glycosylated PrPC at N181 to convert into PrPSc in the
brain.
Results
Both inherited CJDV180I and sporadic VPSPr exhibit no
diglycosylated PrPres
In contrast to sCJD, both fCJDV180I and VPSPr exhibit mono-
and un-glycosylated PK-resistant PrP bands but virtually no
diglycosylated PrP when probed with the 3F4 antibody (Fig. 1A).
However, in the samples that were not treated with PK (Fig. 1B),
diglycosylated PrP was readily detectable not only in sCJD and
non-CJD but also in fCJDV180I and VPSPr. The fCJDT183A
exhibited a very faint diglycosylated PrP band that was visible in
over-exposed blots and is from the wild-type allele as reported
previously [3].
Lack of diglycosylated PrPres is attributable to loss of
glycosylation at the first N-linked glycosylation site in
fCJDV180I and VPSPr
To investigate whether and how the two individual N181 and
N197 sites are associated with the lack of the diglycosylated PrPres
in fCJDV180I and VPSPr, we probed PrP treated with PK or PK
plus PNGase F using V14 and Bar209 antibodies that have been
demonstrated to distinguish mono181 and mono197 but not di-
and unglycosylated PrP (Fig. S1 and S2) [11–14]. On the blot
probed with the Bar209 antibody that specifically detects
mono197, both mono197 and unglycosylated PrP migrating at
,26–28 kDa and ,19–20 kDa, respectively, were detected in all
samples treated with PK alone except for fCJDT183A that had a
significantly under-represented unglycosylated PrP (Fig. 2A).
fCJDT183A exhibited a dominant PrP band migrating at ,26–
28 kDa, corresponding to mono197. In the samples treated with
PK plus PNGase F, only one PrP band migrating at ,19–20 kDa
was observed, corresponding to un- and deglycosylated PrP species
(Fig. 2A). Therefore, mono197 is converted into PrPres in the four
prion diseases examined.
On the blot probed with the V14 antibody that specifically
detects mono181 [11,12], the PrP band migrating at ,24–26 kDa
corresponding to mono181 was detected in sCJD in addition to the
band migrating at ,19–20 kDa corresponding to the unglycosy-
lated PrP (Fig. 2B). In contrast, as in fCJDT183A, no mono181 was
detected in both fCJDV180I and VPSPr, while the unglycosylated
PrP migrating at ,19–20 kDa was detected in all diseases (Fig.
2B). Only the faint under-represented unglycosylated PrP band
migrating at ,19–20 kDa was detected in fCJDT183A. After
treatment with PK plus PNGase F, the un-/de-glycosylated PrP
band migrating at,19–20 kDa was detected in all cases examined
(Fig. 2B). These results suggest that the lack of diglycosylated
PrPres in both VPSPr and fCJDV180I is associated with the absence
of the PK-resistant mono181 as found in fCJDT183A. Notably, the
migration of PrPres from VPSPr-129MV and fCJDV180I was
slightly slower than that of PrPres from sCJD type 2, VPSPr-
129MM and fCJDT183A when probed with V14 and Bar209 [Fig.
2A and 2B], although it was very similar when probed with 3F4
(Fig. 1A). What is responsible for the discrepancy in the migration
of the core PrPres observed when probing with these antibodies
remains to be determined in the future.
Figure 1. Detection of PK-treated and untreated PrP with 3F4.
(A) Brain homogenates from three fCJDV180I (one 129MM and two
129MV, lanes 2–4) and three VPSPr-129MM cases (lanes 5–7) were
treated with PK at 10 mg/ml prior to Western blotting with 3F4. A
sCJDMM2 case was used as a control (lane 1). (B) PrP in brain
homogenates without PK-treatment from fCJDT183A, fCJDV180I, VPSPr,
sCJD and non-CJD was examined by Western blotting.
doi:10.1371/journal.pone.0058786.g001
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To investigate whether there are any changes in the two
monoglycosylated PrP species in the samples prior to PK-
treatment, we examined PrP profiles from VPSPr and fCJDV180I
with the two antibodies in untreated samples. In contrast with PK-
treated PrP, mono181 or mono197 was detected in both VPSPr
and fCJDV180I in addition to C2 and C1, two fragments identified
previously in human brains [11,15], similar to those detected in
the sCJD control (Fig. 2C). Thus, in contrast to fCJDT183A, both
VPSPr and fCJDV180I were found to contain mono181 before PK-
treatment. In combination these data suggests that mono181 is not
converted into PrPres in the two diseases and that mono181 of
VPSPr and fCJDV180I is different from that of sCJD. Notably,
mono197 from all conditions migrated more slowly than did
mono181 at ,0.5–1 kDa, consistent with previous observations
[11,12]. Moreover, the ratio of mono197 intensity to unglycosy-
lated PrP was significantly greater than that of mono181 to
unglycosylated PrP in all three diseases (sCJD: 0.92 6 0.02 vs.
0.43 6 0.08, p, 0.001; VPSPr: 0.81 6 0. 02 vs. 0.486 0.04, p ,
0.001; and fCJDV180I: 1.17 6 0.01 vs. 0.38 6 0.04, p , 0.001)
(Fig. 2C and 2D). Therefore, the lack of diglycosylated PrPres in
fCJDV180I and VPSPr is directly attributable to the absence of PK-
resistant mono181, whereas prior to PK-treatment the proportions
of diglycosylated PrP and mono181 do not appear unusual in the
two diseases.
Neither PK-resistant nor PK-sensitive PrPSc glycosylated
at N181 is detected in both VPSPr and fCJDV180I
To determine whether there is a PK-sensitive mono181 PrPSc in
both VPSPr and fCJDV180I, we isolated total PrPSc using the gene
5 protein (g5p) that has proven to specifically capture not only PK-
resistant but also PK-sensitive PrPSc [6,16]. The PrPSc captured by
g5p was untreated or treated with PK prior to Western blotting
and probing with Bar209 or V14. The Bar209 antibody detected
three PrP bands in untreated sCJD sample corresponding to
mono197 and unglycosylated full-length PrP (Un-) as well as the
endogenously N-terminally truncated PrP fragment called C2,
respectively (Fig. 3A). After PK-treatment, PK-resistant mono197
and unglycosylated PrP were observed (Fig. 3A). Similar to sCJD,
both VPSPr and fCJDV180I also exhibited three PrP bands prior to
PK-treatment (Fig. 3B), while the PK-resistant mono197 and
unglycosylated fragments appeared upon PK-treatment when
probed with Bar209 (Fig. 3B).
When probed with the V14 antibody, mono181, unglycosylated
full-length PrP and C2, respectively, were detected in untreated
sCJD samples (Fig. 3C). The PK-resistant mono181 and
unglycosylated PrP were observed in PK-treated sCJD samples
as well. In contrast, mono181 was not detectable in either
untreated or PK-treated samples from VPSPr and fCJDV180I with
V14 (Fig. 3D). Therefore, neither PK-resistant nor PK-sensitive
PrPSc glycosylated at residue 181 is detectable in either VPSPr or
fCJDV180I.
PrPres from fCJDV180I reveals an electrophoretic profile
similar to that of VPSPr
When probed with 3F4, PrPSc from all six fCJDV180I cases
treated with different amounts of PK exhibited two bands
corresponding to mono- and un-glycosylated PrPres and no
diglycosylated PrPres (Fig. 4A and 4C), the same as VPSPr-
129MM [7]. Moreover, like VPSPr, all cases exhibited the five
bands producing a ladder-like electrophoretic profile (LLEP) when
probed with 1E4, including a predominant 1E4-preferentially-
detectable 7 kDa fragment (Fig. 4B and 4D). PrPSc from
fCJDV180I revealed a higher affinity for 1E4 than for 3F4 (Fig
4A through 4D), another molecular feature of PrPSc observed in
VPSPr. When the PK-treated PrPSc from the two diseases is
compared side by side on the gel, they exhibited virtually identical
migration patterns that are different from those of sCJD (Fig. 4E).
Glycan composition in VPSPr and fCJDV180I is different
from that in sCJD
The finding that di- and mono-glycosylated PrP species carrying
glycans at N181 are unable to form PrPSc may suggest that the
glycan composition at this site in VPSPr and fCJDV180I is different
from that in sCJD. Thus, we compared the binding of ricinus
communis agglutinin I (RCA-I) to PrP glycans. RCA-I recognizes
oligosaccharides ending in galactose/N-acetylgalactosamine
Figure 2. Detection of two individual monoglycosylated PrP
either at N181 or N197. (A) and (B) sCJDMM2 (lanes 1, 2), two VPSPr
(129MM: lanes 3, 4; 129MV: lanes 5, 6), fCJDT183A (lanes 7, 8) and
fCJDV180I (lanes 9, 10) treated with PK or PK plus PNGase F were probed
with Bar209 (A) or V14 (B). (C) PrP from VPSPr, fCJDV180I, and sCJD was
examined with V14 (lanes 1–3) or Bar209 (lanes 4–6). (D) Ratio of mono-
(either mono181 or mono197) to unglycosylated PrP by densitometric
analysis based on three independent experiments, one of which is
presented in (C). The black bar represents mono181:unglyc PrP, while
the grey bar represents mono197:unglyc PrP from sCJD, fCJDV180I or
VPSPr. *** p ,0.005.
doi:10.1371/journal.pone.0058786.g002
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(Galb1-4GlcNAcb1-R) and has previously been used to compare
the differences in glycan composition in different species and prion
strains [17]. RCA-I reacted with both di- and mono-glycosylated
PrP (Fig. S3A). Compared to that in sCJD, in VPSPr and
fCJDV180I, the reactivity of RCA-I with monoglycosylated PrP
decreased [69.65 (sCJD) vs. 55.82 (VPSPr), p = 0.0051 ,0.01;
69.65 (sCJD) vs. 49.49 (fCJDV180I), p = 0.0012 ,0.005], whereas
the reactivity of RCA-I with diglycosylated PrP increased [30.64
(sCJD) vs. 37.70 (VPSPr), p = 0.0012 ,0.005; 30.64 (sCJD) vs.
39.44 (fCJDV180I), p = 0.00027 ,0.001] (Fig. S3B). This result
indicates that glycan composition in VPSPr and fCJDV180I is
indeed different from that in sCJD by an increased amount of
Galb1-4GlcNAcb1-R in the diglycosyl moiety.
There are no detectable differences in profile of
glycosylation and truncation between PrPWt and PrPV180I
expressed in cultured cells
To determine whether the PrPV180I mutation is directly
responsible for the altered glycosylation and proteolytic profiles
observed in fCJDV180I, human neuroblastoma (M17) cells
transfected with human PrPV180I, PrPT183A, or PrPWt with valine
polymorphism at codon 129 were examined by Western blotting
and immunofluorescence confocal microscopy. Western blots
showed no significant differences in glycosylation and N-terminal
truncation profiles between PrPWt and PrPV180I before and after
treatment with PNGase F when probed with 3F4 antibody (Fig.
5A). As expected [9,10], PrPT183A exhibited a dominant mono197
band and a minor unglycosylated PrP band. Neither diglycosy-
lated PrP nor mono181 was observed in PrPT183A. No PrPres was
detected with 3F4 in all three cell lysates treated with PK alone.
After treatment with PK plus PNGase F, a faint PK-resistant
deglycosylated PrP band migrating at ,20 kDa was observed in
the three lysates, while additional undigested full-length PrP was
also detected in PrPT183A (Fig. 5A). In contrast, PrPres was probed
in all PrP species treated with PK alone by using 1E4 (Fig. 5B). As
reported previously [7,10,11,18], while 1E4 exhibits a poor affinity
for untreated PrP, it has a higher affinity for PK-treated PrP
compared to 3F4. In PrPT183A, a dominant mono197 and a minor
unglycosylated PrP but no diglycosylated PrPres were detected,
consistent with our previous observations [10,11]. In contrast with
PrPres detected in the brain homogenates from patients with
fCJDV180I, a PK-resistant PrPV180I detected in cell lysates also
contained diglycosylated form, similar to PrPres in wild-type cell
lysates. Furthermore, faint small PK-resistant PrP fragments
migrating at ,17 kDa and ,7–8 kDa were also detectable in
PrPV180I cell lysates. After treatment with PK plus PNGase F, the
deglycosylated PrPres was observed in PrPT183A, PrPV180I, and
PrPWt, migrating at ,20–21 kDa, consistent with our previous
observations that 1E4 is able to detect a PrPSc-like form in
uninfected brains and cultured cells [10,11,18]. A faint band
migrating at ,17 kDa was detectable in all three cell lysates, while
a faint ,7–8 band was mainly found in PrPV180I and PrPWt (Fig.
5B).
PrPV180I is present in both cell surface and endoplasmic
reticulum
Using immunofluorescence confocal microscope, while
PrPT183A was mainly found in the endoplasmic reticulum (ER)
(Fig. 5C), evidenced by the co-localization of PrP with calnexin, an
ER membrane marker protein, most PrPWt was observed on the
cell surface (Fig. 5E). These results are consistent with previous
observations [10,11]. In contrast, in cells expressing PrPV180I the
PrP staining on the cell surface was reduced compared to cells
expressing PrPWt but higher amounts of PrP were colocalized with
calnexin in the ER (Fig. 5D).
Discussion
Five naturally occurring PrP mutations linked to familial prion
diseases including D178N, V180I, T183A, F198S, and E200K
have reportedly been associated with altered ratios of the three PrP
glycoforms. The PrPT183A mutation completely abolishes the first
N-glycosylation site, a process that reasonably explains the
dramatic decrease or absence of diglycosylated PrP in both PrPC
and PrPSc in the brain and in cultured cells expressing PrPT183A
[3,9–11]. In contrast, in patients with the PrPV180I mutation
adjacent to N181, it is unclear why the absence of diglycosylated
PrP species is evident only in the PK-treated PrPres but not in the
untreated PrP in the brain [4].
Because of the close location to N181, the V180I mutation itself
was originally suggested as preventing glycosylation at N181
position [19]. However, using the N-linked glycosylation predic-
tion algorithm NetNGlyc 1.0 at http://www.cbs.dtu.dk/services/
NetNGlyc/ [11], we predicted a decrease in the glycosylation
potential value for N181 in PrPV180I compared to PrPWt (0.597 vs
0.664) while no potential value was predicted for N181 in
PrPT183A. The prediction data suggest that although the T183A
mutation completely eliminates the N181 glycosylation site, the
V180I mutation may merely alter glycan composition at N181,
which is consistent with the current experimental data. Moreover,
Figure 3. Detection of PrPSc before and after PK-treatment. PrP in P2 fractions from sCJD, VPSPr and fCJDV180I was subjected to g5p-capture
and treatment with or without PK prior to Western blotting with Bar209 (A and B) or V14 (C and D).
doi:10.1371/journal.pone.0058786.g003
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our study with cultured cells revealed that PrPV180I forms PK-
resistant diglycosylated PrPres upon PK-treatment, similar to
PrPWt that was observed previously [10,11]. It is worth noting
that ovine PrPV183I, equivalent to human PrPV180I, also formed
PK-resistant diglycosylated PrP in Rov cells when challenged with
the scrapie strain 127S [20]. Both in vivo and in vitro studies
consistently indicated that PrPV180I shows typical PrP glycoforms
prior to PK-treatment. Furthermore, PrPV180I can form PK-
resistant PrPres spontaneously or acquired by exogenous infection,
as indicated by in vitro cultured cells expressing human PrPV180I or
ovine PrPV183I. However, these results are inconsistent with the
absence of diglycosylated and mono181 PrPres in the brain of
fCJDV180I.
The discrepancy between the in vitro results and the in vivo
findings may be reconciled as follows. The brains of patients with
fCJDV180I contain both mutant and wild-type PrPV180I alleles,
whereas cultured cells express only the mutant allele. Therefore,
we first hypothesize that the glycoform-selective prion formation
pathway observed in the brain involves dominant-negative
inhibition caused by the interaction between misfolded and
normal PrP molecules. Dominant-negative inhibition has been
well documented in a variety of cell and animal models [21–26].
Although the mutant alone is convertible in the cultured cells, its
conversion is inhibited in the brain. This could be because the
interaction of the misfolded PrP caused by the mutation or altered
glycans at N181 with its wild-type counterpart may induce a steric
hindrance around the PrP N181 region (Fig. 6). As a result,
mono197 and unglycosylated PrPC are converted into PrPSc,
whereas mono181 and diglycosylated PrPC with the steric
hindrance are not (Fig. 6). Our hypothesis may be consistent with
the following recent observations. The conformation between the
b2 and a2 loop from residues 165 to 175 has been identified as
associated with a dominant-negative effect [27], which is also
adjacent to the first N-linked glycosylation site. Upon infection of
Rov cells with prion 127S, while each of all five mutants that
removed the second glycosylation site could form PrPres, eight of
nine mutants that removed the first glycosylated site could not
[20]. Furthermore, in response to ME7 strain challenge, Tg mice
lacking the first N-linked site on PrP were resistant, whereas mice
lacking the second site were fully susceptible [28]. Interestingly,
using the serial protein misfolding cyclic amplification technique,
Nishina et al. observed that interactions between different PrPC
glycoforms control the efficiency of prion formation involving
glycan-associated steric hindrance [29]. Using the same method,
the Supattapone group further demonstrated that dominant
negative inhibition of prion formation requires no protein X or
any other accessory cofactor [30]. Therefore, the region from the
loop to the first glycosylation site may be more prone to dominant-
negative inhibition by the steric effect. In the case of VPSPr,
although there is no PrP mutation, a similar aberrant glycosylation
at N181 caused by a rare stochastic event may trigger the
processes as described above for fCJDV180I. Further investigation
on the origin and interaction of alleles and composition of glycans
of PrPSc in the two diseases could address these issues.
Alternatively, the discrepancy between these in vitro results and
the in vivo findings may suggest that the absence of both
diglycosylated and mono181 PrPSc is not attributable to the
mutation itself. This possibility is also supported by our present
finding that although VPSPr shows no mutations in the PrP open
reading frame, PrPres of VPSPr likewise not only lacks the PK-
resistant diglycosylated and mono181 species but also shares the
same LLEP and the immunoreactivity preference. All these
findings suggest that the two diseases bear a similar pathogenetic
mechanism and that fCJDV180I is the familial form of VPSPr. It is
conceivable that one or more co-factors may be operating in
VPSPr and fCJDV180I which may prevent conversion of
diglycosylated PrP and mono181 into PrPSc but trigger conversion
of mono197 and unglycosylated PrP to this unique prion strain.
There are no reports to date showing that fCJDV180I has been
transmitted [31]. Our preliminary study also indicates that the
infectivity of PrPSc from VPSPr seems to be much lower compared
to classic sporadic CJD [32,33]. Although no family history of
neurodegenerative disorders has been reported in fCJDV180I cases,
eight out of 26 reported VPSPr cases showed a familial history of
dementia [7]. Thus, the PrPSc generated through this peculiar
Figure 4. Detection of PrPres in fCJDV180I and VPSPr with 1E4 and 3F4. (A–D) Brain homogenates from six fCJDV180I cases (four 129MM and
two 129MV) were treated with different amounts of PK from 0 to 100 mg/ml prior to Western blotting with 3F4 (A and C) or 1E4 (B and D). (E)
Comparison of PrPres from fCJDV180I, VPSPr, and sCJD probing with 1E4.
doi:10.1371/journal.pone.0058786.g004
Figure 5. Comparison of glycosylation, proteolysis and distri-
bution of PrPT183A, PrPV180I, or PrPWt expressed in cultured
cells. Cell lysates from cultured M17 cells expressing PrPT183A, PrPV180I,
or PrPWt were treated with or without PK and/or PNGase F prior to
Western blotting with 3F4 (A) or 1E4 (B). Subcellular localization of
PrPT183A, PrPV180I and PrPWt (C, D, and E). Immunofluorescence staining
of cells using 3F4 for PrP (green) and calnexin for ER (red). Virtually all
PrPT183A was colocalized with calnexin (C). PrPV180I was also colocalized
with calnexin, but was found on cell surface equally (D). PrP staining
was mostly found on the cell surface in cells expressing PrPWt (E). Scale
bars: 25 mM.
doi:10.1371/journal.pone.0058786.g005
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glycoform-selective process is characterized by the presence of a
unique conformation that forms LLEP upon PK-treatment and
has low infectivity. The other co-factor(s) and how it (they)
selectively alters glycosylation at N181 is yet to be determined.
The striking similarity in the physiochemical and biological
properties of prions found in fCJDV180I and VPSPr favors the
hypothesis that the two conditions share a similar pathogenetic
mechanism although one is associated with mutant PrP and the
other is not [34]. It is worth noting that because of the long disease
duration, multiple PK-resistant PrP fragments, and variable PK-
resistance of PrPSc, VPSPr was once suspected to be the sporadic
form of GSS associated with PrPA117V mutation (GSS-A117V) [7].
In the same study, nevertheless, we indeed observed different
ratios and immunoreactivity of PrPSc between VPSPr and GSS-
A117V [7]. Clearly, whether VPSPr is the sporadic form of
fCJDV180I or GSS-A117V remains to be further determined. It is
conceivable that cells and animals expressing human PrPV180I or
PrPA117V will provide valid models for addressing the outstanding
questions mentioned above.
In conclusion, our findings provide the first evidence based on
patient samples that glycosylation has a significant role in the
formation, selection, and strain trait of prions in spontaneous prion
diseases. These findings are significant not only in enhancing our
understanding of the molecular mechanism of prion formation but
also in developing new therapeutic strategies for prion diseases. In
addition, glycoform-selective process present in prion propagation
may also occur in other neurodegenerative proteinopathies,
notably those sharing prion-like mechanisms [35,36].
Materials and Methods
Subjects and human brain tissues
Nineteen subjects including 10 VPSPr, 6 fCJDV180I, 2 sCJD,
and one fCJDT183A cases were examined. All were referred to the
National Prion Disease Pathology Surveillance Center (NPDPSC,
Cleveland, OH) except for an fCJDV180I case from France [4], and
two fCJDV180I cases from Japan. The six cases with fCJDV180I
were three Caucasian and three Asian patients. Written consent to
use autopsy material for research purposes had been obtained
from patients or legal guardians for all samples. Clinical data and
relevant hospital records were coded and handled according to the
protocols approved by the Ethical Committee and Institutional
Review Board of Case Western Reserve University to protect
patients’ identities. Frozen brain tissues were processed as
previously described [7].
Molecular genetics
The genomic DNA was extracted from frozen brain tissues. The
ORF of the PRNP was amplified by the polymerase chain reaction
(PCR) and PCR products were subjected to automated sequencing
and cloned then sequenced to confirm the mutation and
polymorphisms as previously described [7].
Figure 6. Schematic diagram of glycoform-selective prion formation pathway of PrPV180I in the brain. Four different glycoforms from
the PrPV180I mutant allele (gray) are converted into PK-resistant PrPres in cells. However, in the presence of four glycoforms from the wild-type allele
(black) in the brain, mono181 and diglycosylated PrPWt bind to their mutant counterparts, respectively and the PrPWt-PrPV180I complexes are removed
from the prion conversion pathway due to possible dominant-negative inhibition. So, only mono197 and unglycosylated PrP are converted into
PrPres, whereas mono181 and diglycosylated PrP are not. With Western blotting (WB), 1E4 is able to detect three PK-resistant PrPres including the
diglycosylated form, while 3F4 does not in cells. In contrast, in the brain tissues, 3F4 detects mono197 and unglycosylated PrPres but not
diglycosylated and mono181 PrPres. 1E4 detects five PK-resistant PrPres without diglycosylated form.
doi:10.1371/journal.pone.0058786.g006
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Cloning and production of cell lines
M-17 human neuroblastoma cells were transfected with the
episomal vector pCEP4b containing the coding sequence of a
human wild-type or mutant PrP (T183A or V180I) with valine
polymorphism at codon 129 using the cationic lipid DOTAP
[Roche Applied Science] and prepared as previously described [9–
11,37]. Cell lysates were prepared as described previously [10,11].
Preparation of brain homogenate, S2, and P2 fractions
The 10% (w/v) brain homogenates were prepared in 9 volumes
of lysis buffer (10 mM Tris, 150 mM NaCl, 0.5% Nonidet P-40,
0.5% deoxycholate, 5 mM EDTA, pH 7.4) with pestle on ice.
When required, brain homogenates were centrifuged at 1,000 g
for 10 min at 4uC. In order to prepare S2 and P2 fractions, the
supernatants (S1) were further centrifuged at 35,000 rpm (100,000
g) for 1 hour at 4uC. After the ultracentrifugation, the detergent-
soluble fraction was recovered in the supernatants (S2) while the
detergent-insoluble fraction (P2) was recovered in the pellets that
were resuspended in lysis buffer as described [18].
Specific capture of PrPSc by gene 5 protein and
immunoprecipitation of PrP by 6H4 antibody
The preparation of gene 5 protein (g5p) conjugated magnetic
beads and specific capture of PrPSc by g5p beads were conducted
as previously described [18]. The immunoprecipitation of PrP
from brain homogenates and cell lysates by 6H4-conjugated
magnetic beads was performed as previously described [16,18].
Immunoblotting
Samples treated with or without PK-digestion were resolved on
15% Tris-HCl Criterion (Bio-Rad) as described previously [18].
The following anti-PrP antibodies were used (Fig. S1): mouse
monoclonal antibody (mAb) 3F4 directed against human PrP
residues 106–110 [38,39], 1E4 against human PrP residues 97–
105 [10,18], 6H4 against human PrP144–152 (Prionics AG,
Switzerland), V14 recognizing the human PrP185–196 [11-13],
Pc248 directed against the octarepeat region [12,40], and Bar209
anti-mono197 and unglycosylated PrP mAb [12] (Fig. S1),
recognizing a conformational epitope [12] likely involving human
PrP168-181, like anti-mono197 PrP mAb V61 [12].
Immunofluorescence and confocal microscopy
Immunofluorescence staining of PrP in transfected cells
expressing PrPWt, PrPV180I, or PrPT183A was performed as
previously described [11]. In brief, the cells were fixed in 4%
paraformaldehyde. After blocking with PBST (10% Goat Serum,
2% T-20, 1% Triton X-100), the cells were then incubated with
3F4 (1:10,000) or calnexin (1:1,000) at room temperature, rinsed
with PBS, followed with FITC-conjugated goat anti-mouse IgG at
1:1,000 (Sigma, St. Louis, MO) or Alexa Fluor 568-conjugated
goat anti-rabbit as secondary antibody. Microscopy was per-
formed using a high-speed Leica SP5 Broadband confocal
microscope (Wetzlar, Germany) and HCX PL APO CS 636 oil
immersion objective (NA 1.4). Images were acquired and analyzed
using Leica Application Suite software. Further analysis for
colocalization and correlation was performed using Imaris imaging
suite (Bitplane, St. Paul, MN).
Supporting Information
Figure S1 Schematic diagram of the NMR-derived
structure of human PrP (1) and the epitopes of anti-
PrP antibodies used in this study. The five black five-point
stars represent the octapeptide repeats between residues 51 and
91. The two black right arrows represent the b-sheets. The three
black waves represent the a-helical structures. The two black 7-
point stars represent the two N-linked glycans at residues 181 and
197. The known epitopes of the five antibodies are indicated
including Pc248, 1E4, 3F4, 6H4, and V14. Bar209 has a
conformational epitope (12), which likely involves PrP168–181 as
it recognizes PrPC depending on N181 occupancy, like V61 mAb
(12).
(TIF)
Figure S2 Characterization of the Bar209 antibody by
Western blotting with specific PrP glycoforms. The
following brain homogenates containing different PrP glycoforms
were used (13): tga20 mouse expressing wild type mouse PrP
containing largest amount of di-, intermediate mono-, and smallest
amount of un-glycosylated PrP species (lane 1); Tg mouse
expressing mono197 and unglycosylated PrP without mono181
because of the mutation at the first glycosylation site (arrowhead)
(lane 2); Tg mouse expressing mono181 and unglycosylated PrP
without mono197 because of the mutation at the second
glycosylation site (arrow) (lane 3); and Tg mouse expressing
unglycosylated PrP only because of the mutations at both
glycosylation sites (lane 4). While the control Pc248 antibody
(directed against the anti-octarepeat region of PrPC) is able to
detect all four PrP glycoforms including di-, mono197, mono181,
and un-glycosylated PrP, Bar209 only detects mono197 and
unglycosylated PrP species.
(TIF)
Figure S3 Reactivity of RCA–I with PrP glycans. PrP was
immunoprecipitated by 6H4 from brain homogenates of sCJD,
VPSPr, and fCJDV180I and probed with RCA–I. As a control, the
brain homogenate from sCJD directly loaded onto the gel was
probed with 3F4.
(TIF)
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